SynthesisEuropean radiology2017
The accuracy of
Synthesis in European radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 5 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024Guideline
- What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature.Annals of nuclear medicine · 2023Pooled it
- A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.Breast cancer research and treatment · 2022Guideline
- Prognostic value ofBreast cancer research : BCR · 2020Pooled it
- Diagnostic accuracy of hepatic proton density fat fraction measured by magnetic resonance imaging for the evaluation of liver steatosis with histology as reference standard: a meta-analysis.European radiology · 2019Pooled it
- A first-in-human study of [European journal of nuclear medicine and molecular imaging · 2022Trial
- Association of PET/CT-Derived Metabolic Parameters with Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: An Analysis Across Molecular Subtypes.Diagnostics (Basel, Switzerland) · 2026Article
- A narrative review: key evidence from meta-analyses in nuclear medicine.Annals of nuclear medicine · 2026Review
- Diagnostic Performance ofNPJ breast cancer · 2026Article
- Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art.EJNMMI radiopharmacy and chemistry · 2026Review
- [EJNMMI research · 2026Article
- Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.Medicina (Kaunas, Lithuania) · 2026Article
- FDG PET Hybrid Imaging.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Does FDG PETCT have a predictive value for neoadjuvant chemotherapy response in nonmetastatic breast cancer?Irish journal of medical science · 2025Article
- Peritumoral Adipose Tissue Features Derived from [Journal of personalized medicine · 2024Article
- 18F-FDG-PET/CT in breast cancer imaging: Restaging and Implications for treatment decisions in a clinical practice setting.Acta oncologica (Stockholm, Sweden) · 2024Article
- Can FDG-PET after neoadjuvant chemotherapy plus nivolumab predict residual disease in non-small cell lung cancer?Respirology case reports · 2024Article
- PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives.Journal of clinical medicine · 2024Review
- More on treatment de-escalation, biomarkers of response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: long-term outcomes and translational research findings of the PREDIX HER2 trial.Annals of translational medicine · 2024Article
- Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesThe aim of this meta-analysis was to evaluate the accuracy of
methodsPubMed, Embase, the Cochrane Library (Central), and the Web of Science (SCI-Expanded) were systematically searched to identify pertinent studies. The methodologic quality of the included studies was assessed by the Quality Assessment of Diagnostic Accuracy Studies-2. The Spearman correlation coefficient was used to explore the existence of a threshold effect. Heterogeneity was assessed by the likelihood ratio I
resultsThe pooled values calculated with a mixed-effects model for the sensitivity, specificity and diagnostic odds ratio with 95% confidence intervals were 81.9% (76.0-86.6%), 79.3% (72.1-85.1%) and 17.35 (10.98-27.42), respectively.
conclusionsKEY POINTS: • This meta-analysis assesses the role of PET/CT in breast cancer during NAC. • Pathological responses were based on both primary tumour and lymph node. •
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.